Immunotherapeutic strategies in breast cancer: A clinical update.
Jennifer Q ZhangGeorge PlitasPublished in: Journal of surgical oncology (2020)
Immunotherapy has been incorporated into the standard of care for a wide range of malignancies. The study of tumor-infiltrating lymphocytes has emphasized the importance of the host antitumor immune response in the natural history of breast cancer. Recent clinical trials have used immunotherapeutic approaches to augment this response and improve outcomes for patients with breast cancer. Here, we review several current clinical trial data that indicate checkpoint blockade may mediate clinically significant responses.
Keyphrases
- clinical trial
- immune response
- phase ii
- healthcare
- dna damage
- palliative care
- open label
- study protocol
- quality improvement
- electronic health record
- phase iii
- cell cycle
- randomized controlled trial
- peripheral blood
- skeletal muscle
- pain management
- dendritic cells
- metabolic syndrome
- adipose tissue
- cell proliferation
- artificial intelligence